| Title |
Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure
|
|---|---|
| Published in |
Drug Design, Development and Therapy, May 2021
|
| DOI | 10.2147/dddt.s308863 |
| Pubmed ID | |
| Authors |
Osama A Badary, Marwa S Hamza, Rajiv Tikamdas |
| Abstract |
COVID-19 has caused a major global health crisis, as excessive inflammation, oxidation, and exaggerated immune response in some sufferers can lead to a condition known as cytokine storm, which may progress to acute respiratory distress syndrome (ARDs), which can be fatal. So far, few effective drugs have emerged to assist in the treatment of patients with COVID-19, though some herbal medicine candidates may assist in the fight against COVID-19 deaths. Thymoquinone (TQ), the main active ingredient of black seed oil, possesses antioxidant, anti-inflammatory, antiviral, antimicrobial, immunomodulatory and anticoagulant activities. TQ also increases the activity and number of cytokine suppressors, lymphocytes, natural killer cells, and macrophages, and it has demonstrated antiviral potential against a number of viruses, including murine cytomegalovirus, Epstein-Barr virus, hepatitis C virus, human immunodeficiency virus, and other coronaviruses. Recently, TQ has demonstrated notable antiviral activity against a SARSCoV-2 strain isolated from Egyptian patients and, interestingly, molecular docking studies have also shown that TQ could potentially inhibit COVID-19 development through binding to the receptor-binding domain on the spike and envelope proteins of SARS-CoV-2, which may hinder virus entry into the host cell and inhibit its ion channel and pore forming activity. Other studies have shown that TQ may have an inhibitory effect on SARS CoV2 proteases, which could diminish viral replication, and it has also demonstrated good antagonism to angiotensin-converting enzyme 2 receptors, allowing it to interfere with virus uptake into the host cell. Several studies have also noted its potential protective capability against numerous chronic diseases and conditions, including diabetes, hypertension, dyslipidemia, asthma, renal dysfunction and malignancy. TQ has recently been tested in clinical trials for the treatment of several different diseases, and this review thus aims to highlight the potential therapeutic effects of TQ in the context of the COVID-19 pandemic. |
X Demographics
The data shown below were collected from the profiles of 232 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 48 | 21% |
| United Kingdom | 4 | 2% |
| Canada | 4 | 2% |
| India | 3 | 1% |
| Comoros | 2 | <1% |
| Malaysia | 2 | <1% |
| Japan | 1 | <1% |
| Mexico | 1 | <1% |
| Solomon Islands | 1 | <1% |
| Other | 14 | 6% |
| Unknown | 152 | 66% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 214 | 92% |
| Practitioners (doctors, other healthcare professionals) | 11 | 5% |
| Scientists | 6 | 3% |
| Science communicators (journalists, bloggers, editors) | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 206 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 206 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 20 | 10% |
| Student > Ph. D. Student | 19 | 9% |
| Student > Master | 12 | 6% |
| Student > Doctoral Student | 12 | 6% |
| Researcher | 11 | 5% |
| Other | 30 | 15% |
| Unknown | 102 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 14% |
| Biochemistry, Genetics and Molecular Biology | 19 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 6% |
| Chemistry | 6 | 3% |
| Psychology | 5 | 2% |
| Other | 21 | 10% |
| Unknown | 114 | 55% |
Attention Score in Context
This research output has an Altmetric Attention Score of 192. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2024.
All research outputs
#212,100
of 25,834,578 outputs
Outputs from Drug Design, Development and Therapy
#19
of 2,284 outputs
Outputs of similar age
#6,240
of 456,631 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 52 outputs
Altmetric has tracked 25,834,578 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 456,631 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.